631 related articles for article (PubMed ID: 11090543)
1. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.
Yu Z; Xu F; Huse LM; Morisseau C; Draper AJ; Newman JW; Parker C; Graham L; Engler MM; Hammock BD; Zeldin DC; Kroetz DL
Circ Res; 2000 Nov; 87(11):992-8. PubMed ID: 11090543
[TBL] [Abstract][Full Text] [Related]
2. Differential cardiotoxicity in response to chronic doxorubicin treatment in male spontaneous hypertension-heart failure (SHHF), spontaneously hypertensive (SHR), and Wistar Kyoto (WKY) rats.
Sharkey LC; Radin MJ; Heller L; Rogers LK; Tobias A; Matise I; Wang Q; Apple FS; McCune SA
Toxicol Appl Pharmacol; 2013 Nov; 273(1):47-57. PubMed ID: 23993975
[TBL] [Abstract][Full Text] [Related]
3. Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney.
Yu Z; Huse LM; Adler P; Graham L; Ma J; Zeldin DC; Kroetz DL
Mol Pharmacol; 2000 May; 57(5):1011-20. PubMed ID: 10779386
[TBL] [Abstract][Full Text] [Related]
4. Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles.
Gauthier KM; Olson L; Harder A; Isbell M; Imig JD; Gutterman DD; Falck JR; Campbell WB
Am J Physiol Renal Physiol; 2011 Oct; 301(4):F765-72. PubMed ID: 21753077
[TBL] [Abstract][Full Text] [Related]
5. Increases in plasma trans-EETs and blood pressure reduction in spontaneously hypertensive rats.
Jiang H; Quilley J; Doumad AB; Zhu AG; Falck JR; Hammock BD; Stier CT; Carroll MA
Am J Physiol Heart Circ Physiol; 2011 Jun; 300(6):H1990-6. PubMed ID: 21398593
[TBL] [Abstract][Full Text] [Related]
6. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats.
Ghosh S; Chiang PC; Wahlstrom JL; Fujiwara H; Selbo JG; Roberds SL
Basic Clin Pharmacol Toxicol; 2008 May; 102(5):453-8. PubMed ID: 18312493
[TBL] [Abstract][Full Text] [Related]
7. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha.
Fang X; Hu S; Xu B; Snyder GD; Harmon S; Yao J; Liu Y; Sangras B; Falck JR; Weintraub NL; Spector AA
Am J Physiol Heart Circ Physiol; 2006 Jan; 290(1):H55-63. PubMed ID: 16113065
[TBL] [Abstract][Full Text] [Related]
8. Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat.
Sellers KW; Sun C; Diez-Freire C; Waki H; Morisseau C; Falck JR; Hammock BD; Paton JF; Raizada MK
FASEB J; 2005 Apr; 19(6):626-8. PubMed ID: 15659536
[TBL] [Abstract][Full Text] [Related]
9. 5,6-epoxyeicosatrienoic acid mediates the enhanced renal vasodilation to arachidonic acid in the SHR.
Pomposiello SI; Quilley J; Carroll MA; Falck JR; McGiff JC
Hypertension; 2003 Oct; 42(4):548-54. PubMed ID: 12939232
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha.
Ng VY; Huang Y; Reddy LM; Falck JR; Lin ET; Kroetz DL
Drug Metab Dispos; 2007 Jul; 35(7):1126-34. PubMed ID: 17431031
[TBL] [Abstract][Full Text] [Related]
11. Increases in levels of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids (EETs and DHETs) in liver and heart in vivo by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and in hepatic EET:DHET ratios by cotreatment with TCDD and the soluble epoxide hydrolase inhibitor AUDA.
Diani-Moore S; Ma Y; Gross SS; Rifkind AB
Drug Metab Dispos; 2014 Feb; 42(2):294-300. PubMed ID: 24311719
[TBL] [Abstract][Full Text] [Related]
12. Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy.
Noh MR; Jang HS; Salem FE; Ferrer FA; Kim J; Padanilam BJ
Am J Physiol Renal Physiol; 2023 Feb; 324(2):F138-F151. PubMed ID: 36475868
[TBL] [Abstract][Full Text] [Related]
13. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition.
Fang X; Kaduce TL; Weintraub NL; Harmon S; Teesch LM; Morisseau C; Thompson DA; Hammock BD; Spector AA
J Biol Chem; 2001 May; 276(18):14867-74. PubMed ID: 11278979
[TBL] [Abstract][Full Text] [Related]
14. Beyond detoxification: a role for mouse mEH in the hepatic metabolism of endogenous lipids.
Marowsky A; Meyer I; Erismann-Ebner K; Pellegrini G; Mule N; Arand M
Arch Toxicol; 2017 Nov; 91(11):3571-3585. PubMed ID: 28975360
[TBL] [Abstract][Full Text] [Related]
15. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition.
Larsen BT; Miura H; Hatoum OA; Campbell WB; Hammock BD; Zeldin DC; Falck JR; Gutterman DD
Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H491-9. PubMed ID: 16258029
[TBL] [Abstract][Full Text] [Related]
16. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension.
Imig JD; Zhao X; Capdevila JH; Morisseau C; Hammock BD
Hypertension; 2002 Feb; 39(2 Pt 2):690-4. PubMed ID: 11882632
[TBL] [Abstract][Full Text] [Related]
17. Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats.
Elmarakby AA; Faulkner J; Pye C; Rouch K; Alhashim A; Maddipati KR; Baban B
Clin Sci (Lond); 2013 Oct; 125(7):349-59. PubMed ID: 23611540
[TBL] [Abstract][Full Text] [Related]
18. Increased epoxyeicosatrienoic acids and reduced soluble epoxide hydrolase expression in the preeclamptic placenta.
Dalle Vedove F; Fava C; Jiang H; Zanconato G; Quilley J; Brunelli M; Guglielmi V; Vattemi G; Minuz P
J Hypertens; 2016 Jul; 34(7):1364-70. PubMed ID: 27115337
[TBL] [Abstract][Full Text] [Related]
19. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels.
Fang X; Weintraub NL; McCaw RB; Hu S; Harmon SD; Rice JB; Hammock BD; Spector AA
Am J Physiol Heart Circ Physiol; 2004 Dec; 287(6):H2412-20. PubMed ID: 15284062
[TBL] [Abstract][Full Text] [Related]
20. Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy.
Chen G; Xu R; Wang Y; Wang P; Zhao G; Xu X; Gruzdev A; Zeldin DC; Wang DW
Am J Physiol Endocrinol Metab; 2012 Sep; 303(5):E563-75. PubMed ID: 22739108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
